{"filing":{"accession_number":"0001185185-26-003895","cik":"0001729214","ticker":"XRTX","company_name":"XORTX Therapeutics Inc.","form":"6-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"xortx6k090926.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1729214/000118518526003895/xortx6k090926.htm"},"events":[{"id":32310,"run_id":29686,"accession_number":"0001185185-26-003895","anchor_item_number":"EX-99.2","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"XORTX Therapeutics re-engaged IR Agency LLC for investor relations and marketing services following completion of its voluntary delisting from the TSX Venture Exchange, under a revised consulting agreement valued at US$2.5 million over three months.","company_name":"XORTX Therapeutics Inc.","ticker":"XRTX","filing_date":"2026-09-09","form":"6-K","submitted_at":null,"items":[{"id":35456,"accession_number":"0001185185-26-003895","item_number":"EX-99.1","item_title":"xortxex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This announcement discloses XORTX's re-engagement of IR Agency LLC for investor relations and marketing services following completion of its voluntary delisting from the TSX Venture Exchange. The engagement is on substantially the same terms previously disclosed. This is a routine administrative and governance matter concerning investor relations contractor services, not a material event affecting the registrant's financial condition, operations, or compliance status. The delisting itself (already completed) is not the subject of this announcement; the announcement merely notes the timing of the IR re-engagement relative to that prior event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:03:15.467220+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35457,"accession_number":"0001185185-26-003895","item_number":"EX-99.2","item_title":"xortxex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit discloses a material change involving the Company's entry into a revised consulting agreement with IR Agency LLC for investor relations and marketing services following completion of its voluntary delisting from the TSX Venture Exchange. The agreement is valued at US$2.5 million over three months. While the delisting itself might constitute a separate material event (potentially `delisting_risk`), this exhibit focuses on the operational consequence—the engagement of an IR consultant post-delisting—which is a strategic business decision rather than a governance, financial, or legal event fitting the named categories. The materiality is supported by the significant fee and the Company's explicit designation as a \"material change\" under Canadian securities law (Form 51-102F3).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:03:15.467220+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35456,"accession_number":"0001185185-26-003895","item_number":"EX-99.1","item_title":"xortxex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This announcement discloses XORTX's re-engagement of IR Agency LLC for investor relations and marketing services following completion of its voluntary delisting from the TSX Venture Exchange. The engagement is on substantially the same terms previously disclosed. This is a routine administrative and governance matter concerning investor relations contractor services, not a material event affecting the registrant's financial condition, operations, or compliance status. The delisting itself (already completed) is not the subject of this announcement; the announcement merely notes the timing of the IR re-engagement relative to that prior event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:03:15.467220+00:00","company_name":"XORTX Therapeutics Inc.","ticker":"XRTX","filing_date":"2026-09-09"},{"id":35457,"accession_number":"0001185185-26-003895","item_number":"EX-99.2","item_title":"xortxex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit discloses a material change involving the Company's entry into a revised consulting agreement with IR Agency LLC for investor relations and marketing services following completion of its voluntary delisting from the TSX Venture Exchange. The agreement is valued at US$2.5 million over three months. While the delisting itself might constitute a separate material event (potentially `delisting_risk`), this exhibit focuses on the operational consequence—the engagement of an IR consultant post-delisting—which is a strategic business decision rather than a governance, financial, or legal event fitting the named categories. The materiality is supported by the significant fee and the Company's explicit designation as a \"material change\" under Canadian securities law (Form 51-102F3).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:03:15.467220+00:00","company_name":"XORTX Therapeutics Inc.","ticker":"XRTX","filing_date":"2026-09-09"}]}